Sign In
Buy FATE
$2.22
-0.350 (-13.62%)
At Close: Jun 03, 2026
3 Monster Growth Stocks That Are Still Undervalued
12:33pm, Thursday, 30'th Apr 2020
The market is on the move, and this time stocks took off on an upward trajectory. On Wednesday April 29, all three of the major U.S. stock indexes posted gains at the closing bell, climbing higher on
Fate Therapeutics (FATE) Gets a Buy Rating from Mizuho Securities
01:07pm, Wednesday, 29'th Apr 2020
Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on Fate Therapeutics (FATE – Research Report) today and set a
Is Fate Therapeutics a Buy?
11:11am, Wednesday, 29'th Apr 2020
The cell therapy pioneer has a promising early-stage pipeline and just landed a huge partner. What should investors make of this high-risk, high-reward stock?
Fate Therapeutics (NASDAQ:FATE) Rating Lowered to Hold at Zacks Investment Research
07:54am, Wednesday, 29'th Apr 2020
Fate Therapeutics (NASDAQ:FATE) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Monday, Zacks.com reports. According to Zacks, �
Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the pres
Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: Should You Buy?
04:33pm, Tuesday, 28'th Apr 2020
Fate Therapeutics (FATE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: Should You Buy?
04:33pm, Tuesday, 28'th Apr 2020
Fate Therapeutics (FATE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Boeing Backs Out From A Joint Venture With Embraer, Fate Of C-390 Cargo Plane Uncertain
03:53pm, Tuesday, 28'th Apr 2020
Boeing announced that it is withdrawing from a joint venture with the Brazilian aircraft maker Embraer.
Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: Should You Buy?
12:00am, Tuesday, 28'th Apr 2020Fate Therapeutics (NASDAQ:FATE) Upgraded to "Buy" at Zacks Investment Research
06:18am, Monday, 20'th Apr 2020
Zacks Investment Research upgraded shares of Fate Therapeutics (NASDAQ:FATE) from a hold rating to a buy rating in a research report report published on Thursday morning, Zacks.com reports. The firm c
Bank of America Corp DE Trims Stake in Fate Therapeutics Inc (NASDAQ:FATE)
08:20am, Sunday, 19'th Apr 2020
Bank of America Corp DE decreased its position in shares of Fate Therapeutics Inc (NASDAQ:FATE) by 5.0% during the 4th quarter, according to the company in its most recent disclosure with the Securiti
Fate Therapeutics (NASDAQ:FATE) & Solid Biosciences (NASDAQ:SLDB) Financial Analysis
06:16am, Sunday, 19'th Apr 2020
Solid Biosciences (NASDAQ:SLDB) and Fate Therapeutics (NASDAQ:FATE) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their ins
Fate Therapeutics (NASDAQ:FATE) Downgraded by Zacks Investment Research
06:06am, Saturday, 18'th Apr 2020
Zacks Investment Research downgraded shares of Fate Therapeutics (NASDAQ:FATE) from a buy rating to a hold rating in a research report sent to investors on Wednesday, Zacks.com reports. According to Z
Fate Therapeutics Inc (NASDAQ:FATE) Shares Purchased by Alliancebernstein L.P.
09:40am, Friday, 17'th Apr 2020
Alliancebernstein L.P. increased its holdings in shares of Fate Therapeutics Inc (NASDAQ:FATE) by 4.1% in the fourth quarter, according to the company in its most recent filing with the Securities and
-$0.38 EPS Expected for Fate Therapeutics Inc (NASDAQ:FATE) This Quarter
10:16am, Thursday, 16'th Apr 2020
Equities research analysts expect Fate Therapeutics Inc (NASDAQ:FATE) to post ($0.38) earnings per share for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for
